TalkMed Group Limited, an investment holding company, provides medical oncology, stem cell transplants, palliative care, and other related services in Singapore, China, Hong Kong, Vietnam, India, New Zealand, Australia, and the United States. It operates through two segments: Oncology Services; and Cellular and Gene Therapy Related Products and Services. The company offers medical oncology services in the areas of breast, colon, lung, liver, biliary and pancreatic, gastro-intestinal, head and neck, genitourinary and gynaecological, and haematology malignancies and brain cancers, as well as lymphoma and leukaemia. It also provides palliative care services comprising cancer pain management, discharge and home care planning, advance care planning, and end-of-life care planning; and ancillary health services, such as CANSCREEN, a screening program that provides screening for individuals at a risk of getting cancer. In addition, the company is involved in the goods and services related to cellular and gene therapy; specialist doctors and clinical staff services; and healthcare management services. Further, the company develops novel processing platforms for cell and gene therapy and carrying out research in genetic modification of immune cells; and novel platform viral vector technologies that strive to advance genetic modification of cellular therapy through basic vector system design. TalkMed Group Limited was founded in 1997 and is based in Singapore. TalkMed Group Limited operates as a subsidiary of Citibank Nominees Singapore Pte Ltd.